CD45 Antibody: How Does Targeting the Leukocyte Common Antigen Pioneer a New Paradigm in Blood Cancer Treatment?

1. What are the biological characteristics and functional mechanisms of CD45 molecules?

CD45, also known as protein tyrosine phosphatase receptor type C or leukocyte common antigen, is a transmembrane glycoprotein with a molecular weight of 180-220kDa that is expressed on all hematopoietic cells except mature erythrocytes. The molecule consists of a highly conserved intracellular phosphatase domain, transmembrane region, and extracellular region. Its gene is located in the human chromosome 1q31-32 region and contains 35 exons. Through alternative splicing of exons 4/5/6/7, CD45 can generate multiple isoforms. The specific expression patterns of these isoforms in different immune cell subsets provide important basis for immune cell typing. At the functional level, CD45 plays a key role in T cell receptor and B cell receptor signal transduction by regulating LCK and SRC kinase activity, while also participating in cytokine pathway regulation and lymphocyte survival maintenance.

2. What are the key technical challenges in CD45-targeted therapy?

The main obstacle in developing CD45-targeted therapies lies in its broad expression across all hematopoietic cells, including therapeutic immune effector cells. Traditional targeting strategies would cause "fratricide" among therapeutic cells, severely limiting treatment efficacy. Recent studies have used CRISPR-mediated epitope editing technology to precisely modify CD45 on the surface of T cells and hematopoietic stem cells, allowing them to retain normal biological functions while avoiding recognition by CAR-T cells. This innovative approach lays the foundation for developing universal blood cancer treatment regimens and provides new research ideas for other widely expressed targets.

3. What is the current status and strategy of CD45-targeted drug development?

Current therapeutic development targeting CD45 mainly focuses on three directions: radioimmunoconjugates, antibody-drug conjugates, and cell therapy products. The most advanced are radioimmunoconjugates, which have entered Phase III clinical trials. These drugs precisely eliminate CD45-positive cells by conjugating radioactive isotopes with CD45 antibodies. In key clinical trials for acute myeloid leukemia, this therapy demonstrated significant advantages: treated patients maintained complete remission for over 6 months, and all successfully underwent bone marrow transplantation, while only 17% of control group patients met transplantation criteria.

4. What are the breakthrough applications of epitope editing technology in CD45-targeted therapy?

Epitope editing technology precisely alters the amino acid sequence of specific antigenic epitopes on CD45 protein, making it unrecognizable by therapeutic antibodies while fully retaining its natural biological functions. This precise gene editing strategy successfully addresses the core challenge in CD45-targeted therapy. Studies confirm that edited T cells not only avoid fratricide but also maintain normal signal transduction and effector functions. Similarly, edited hematopoietic stem cells can successfully engraft and reconstruct a complete hematopoietic system. This technological breakthrough enables the development of "universal" blood cancer treatment regimens.

5. What are the significant clinical advantages of CD45-targeted therapy?

Clinical research data show that CD45-targeted therapy demonstrates multiple advantages in hematological malignancies. Regarding safety, compared with traditional treatments, it significantly reduces the incidence of severe complications like sepsis. In terms of efficacy, it not only improves tumor cell clearance efficiency but also creates favorable conditions for subsequent stem cell transplantation. Notably, this therapy enables more patients who originally didn't meet transplantation criteria to receive transplants, significantly improving long-term survival prognosis. These advantages make CD45 a highly promising target in hematological malignancy treatment.

6. What are the future development directions for CD45-targeted therapy?

With continuous advancements in gene editing and antibody engineering technologies, CD45-targeted therapy will develop toward greater precision and safety. Future research priorities include optimizing editing efficiency, developing new conjugation strategies, and exploring combination therapies. Combining CD45-targeted therapy with other immunotherapies may produce synergistic antitumor effects. As understanding of CD45's biological functions deepens, personalized treatment strategies for different disease stages and patient populations will gradually improve. These advances will collectively promote widespread clinical application of CD45-targeted therapy.

7. Conclusion

As a key regulatory molecule widely expressed on hematopoietic cells, CD45-targeted strategies have successfully overcome self-targeting challenges through innovative epitope editing technology, opening new avenues for blood cancer treatment. From radioimmunoconjugates to genetically engineered cell therapies, the CD45-targeting platform demonstrates tremendous therapeutic potential. With continuous technological optimization and clinical experience accumulation, CD45-targeted therapy is expected to become an important component of blood cancer treatment systems, bringing hope for cure to more patients.

8. Which manufacturers provide CD45 antibodies?Hangzhou Start Biotech Co., Ltd. has independently developed the "S-RMab® CD45 Recombinant Rabbit Monoclonal Antibody" (Product Name: S-RMab® CD45 Recombinant Rabbit mAb (SDT-R035), a leukocyte common antigen detection antibody with high specificity, excellent sensitivity, and outstanding staining consistency. This product was developed using the proprietary S-RMab® recombinant rabbit monoclonal antibody technology platform and has been rigorously validated across multiple technical platforms including immunohistochemistry (IHC). It holds critical application value in hematopoietic system tumor diagnosis, inflammatory cell identification, and minimal residual disease detection.

Professional Technical Support: We provide comprehensive product technical documentation, including complete IHC experimental protocols, optimized antigen retrieval solutions, and professional interpretation guidance, fully assisting customers in obtaining accurate and reliable results in hematopathology and immunology research.

Hangzhou Start Biotech Co., Ltd. is committed to providing high-quality, high-value biological reagents and solutions for global innovative pharmaceutical companies and research institutions. For more details about the "S-RMab® CD45 Recombinant Rabbit Monoclonal Antibody" or to request sample testing, please contact us.

Product Information